News | Page 7 of 7 | 53Biologics

February 15, 2020 Patricia De La Madrid Comments: 0

Revolutionizing Vaccine Production: Our ARNm Synthesis Enzymes Project

In response to the urgent need for increased vaccine manufacturing capacity amidst the COVID-19 pandemic, we are proud to announce our latest project: the development of a new industrial production process for ARNm synthesis enzymes. Supported by the ERDF of the European Union and the Junta de Castilla y León, this initiative aims to address the critical shortage of vaccine supplies by enhancing the efficiency and scalability of production. By leveraging cutting-edge technology and strategic pa...

C1-Expressed Biosimilar Breakthrough

We’re thrilled to announce our latest endeavor: the research and development of a C1-expressed biosimilar certolizumab for the treatment of inflammatory diseases. This groundbreaking project, generously funded by the ERDF of the European Union and the Junta de Castilla y León through the ICE, underscores our commitment to pushing the boundaries of biopharmaceutical innovation. With the ultimate goal of improving patient outcomes and advancing the field of biomedicine, this project represe...

Awarded the first place medal of the quality seal

We are so happy to announce that we have been awarded the ISO 9001:2015 quality seal Trophy First place medal This quality policy is based on a firm commitment with our clients to meet their requirements and expectations. About 53Biologics: 53Biologics is a CDMO with specialized in biologics production. It is a leading biopharma company providing services from preclinical and clinical development to GMP manufacturing, supporting our clients in getting their biological products to market as quick...